SHARE

AstraZeneca sees revenue growth in 2025, driven by strong oncology sales

The UK’s most valuable listed company reported 2025 revenue of $58.7bn, up 8%, with oncology sales rising 14%. Core earnings per share rose 11% to $9.16. The drugmaker highlighted 16 positive late-stage trial results and reaffirmed its $80bn 2030 target.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.